Beijing Aosaikang Pharmaceutical Co.,ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Aosaikang Pharmaceutical Co., Ltd. was established in 2003 and originated from Nanjing Haiguang Applied Chemistry Research Institute, one of the earliest private new drug research and development institutions in Jiangsu Province. In 2019, Aosaikang officially landed on the capital market under the stock code SZ.002755. Aosaikang always adheres to the corporate philosophy of "research as the source and health as the foundation", integrating innovation into the company's genes and taking innovation as the source of enterprise development. Since the successful launch of the first domestically produced proton pump inhibitor (PPI) injection, Oxycon (Omeprazole Sodium for Injection), Oxycon has developed into a high-tech enterprise that integrates pharmaceutical research and development, production, market promotion, and sales. It is one of the top 100 enterprises in the national pharmaceutical industry and a major local taxpayer. At present, Oxycon products cover four treatment areas: digestion, anti-tumor, chronic diseases, and resistance to drug-resistant infections. The company has been awarded the honorary titles of "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line" and "China Innovative Pharmaceutical Enterprise" for many consecutive years. |
| Headquarter | Beijing |
| Establish Date | 12/24/1996 |
| Listed Code | 002755.SZ |
| Listed Date | 5/15/2015 |
| Chairman | Chen Qingcai. |
| CEO | Ma Jingfei. |
| Website | www.ask-pharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
